The U.S. Food and Drug Administration approved Amgen Inc.’s biosimilar copy of Johnson & Johnson’s blockbuster rheumatoid arthritis (RA) drug Remicade.
CymaBay Therapeutics Inc. is scrapping two mid-stage trials of the liver disease drug seladelpar after biopsies found a type of liver damage in some patients, sending the company’s shares down more than 75 percent.
Researchers Working to Understand Why Some Patients with Autoimmune Diseases Develop Diabetes Instead of Arthritis
Arthritis, Autoimmune Diseases, Autoimmune inflammation, Beta cells, Diabetes, Genes, Immune Cells, Inflammatory Bowel Disease, Insulin, Multiple Sclerosis, National Institutes of Health, Nature Genetics, Pancreatic beta cells, Pluripotential cells, Researchers, Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Type 1 DiabetesRecently published research in the journal Nature Genetics found significant insight into this question: Why does a patient with an autoimmune disease become a type 1 diabetic rather than have rheumatoid arthritis?
Dragonfly Therapeutics and AbbVie forged a multi-target research collaboration to advance new treatment options for autoimmune and oncology indications.
Bristol-Myers Squibb Co. and Celgene Corp. won U.S. antitrust approval for their merger on condition that they sell Celgene’s psoriasis drug Otezla.
AstraZeneca Plc’s experimental treatment anifrolumab significantly reduced disease activity in patients with the autoimmune disorder lupus in a late-stage study.
Mallinckrodt receives SEC subpoena over Acthar gel lawsuit
Addictions, Business, Centers for Medicare and Medicaid Services (CMS), Department of Health and Human Services (HHS), Gels, Generics, Infantile Spasms, Lawsuits, Manufacturing, Multiple Sclerosis, Opioid Litigation, Opioids, Shares, U.S. Securities and Exchange Commission (SEC)Mallinckrodt Plc received a subpoena from the U.S. Securities and Exchange Commission for documents related to the drugmaker’s lawsuit against the U.S. Department of Health and Human Services (HHS).
The U.S. Food and Drug Administration approved Vumerity (diroximel fumarate) – a novel oral fumarate with a distinct chemical structure – for the treatment of relapsing forms of multiple sclerosis.
Despite the success Gilead Sciences has experienced with the JAK inhibitor filgotinib in rheumatoid arthritis, the medication failed to hit the mark in mid-stage trials aimed at lupus and Sjogren’s syndrome.
Acorda Therapeutics will terminate approximately 25 percent of headcount as the company initiates a corporate restructuring.
